BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HS-10380 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HS-10380\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07759869-9280@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:HS-10380: Phase 3 readout est. (NCT07759869)
DESCRIPTION:HS-10380\, phase 3\, Schizophrenia.\nStudy: A Study to Evaluate
  the Long-term Safety of HS-10380 in Patients With Schizophrenia\nEstimate
 d primary completion: 31 July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hs-10380#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07759869
URL:https://assetmemo.bio/drug/hs-10380#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911787-9280@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20290124
DTEND;VALUE=DATE:20290125
SUMMARY:HS-10380: Phase 3 readout est. (NCT07911787)
DESCRIPTION:HS-10380\, phase 3\, Schizophrenia.\nStudy: Phase 3 Study of HS
 -10380 for Acute Schizophrenia in Chinese Adults\nEstimated primary comple
 tion: 24 January 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/hs-10380#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07911787
URL:https://assetmemo.bio/drug/hs-10380#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
